Prescription Drugs — Not Broke Consumers — Caused Walmart's Big Sales Whiff

Walmart raised its full-year sales and profit outlook after Q2 revenue rose 5.9% to $187.9B, beating the $186.8B consensus—but the stock fell on U.S. comp sales growth of just 2.6% (a rare miss). Management estimated falling prescription drug prices cut comp growth by 80–90 bps, implying comps closer to ~3.4% ex-pharmacy price deflation, helped by rising prescription volumes in GLP-1/diabetes therapies. Investors also flagged a slowdown in U.S. transaction growth to 1.5% from 3% earlier and margin pressure from higher fuel/freight, leaving the demand picture mixed despite the revenue beat.

Analysis

The market is likely conflating a reporting issue with a demand issue. The key mechanism is pharmacy deflation: lower reimbursement rates can depress reported sales even when unit demand is healthy, so the selloff in WMT looks more like a misunderstanding of mix than a true deterioration in consumer behavior. If that’s right, the immediate downside is mostly sentiment-driven and should fade over the next 1-3 months as investors reframe the quarter around underlying traffic and market share rather than nominal revenue.

The real economic pressure point is CVS and other pharmacy-heavy businesses, where prescription price deflation hits top-line optics and can also narrow spread capture if payor/PBM economics lag. That creates a second-order winner/loser dynamic: WMT’s pharmacy deflation is a reporting headwind, but CVS has more direct exposure to the same pricing trend without WMT’s broader retail offset. The larger structural risk for WMT is not the script price effect itself; it’s that transaction growth deceleration hints lower-income consumers are still under strain, which would show up later in grocery mix, discretionary weakness, and margin pressure from freight/fuel absorption.

Contrarian view: the consensus may be over-discounting a one-time explanation while underestimating how much of WMT’s valuation depends on sustained traffic momentum. If transaction growth stays near current levels or slips further, the “pharmacy excuse” will stop working. Watch next quarter’s U.S. transactions, gross margin, and guidance language as the falsifiers; a re-acceleration there should re-open multiple expansion, while another sub-2% comp print would validate a more cautious stance.

Key Decisions for Investors

• Buy WMT on weakness for a 1-3 month mean-reversion trade; the selloff looks overstated if the comp miss is mostly pharmacy-price deflation. Falsify if next U.S. comp trends stay near 2.5% or gross margin guidance is cut.
• Pair trade: long WMT / short CVS over 6-12 weeks to express the view that pharmacy deflation is a reporting headwind for WMT but a more direct revenue and spread headwind for CVS. Risk: CVS managed-care offset or better-than-expected pharmacy mix.
• If WMT remains weak into the next earnings window, consider a defined-risk bullish structure (bull call spread) rather than outright stock; the catalyst is a narrative reset, not a new fundamental inflection. Use a 1-3 month tenor.
• Avoid shorting TGT off this print alone; its better comp suggests the consumer is not uniformly cracking. If anything, use TGT as a relative benchmark for whether WMT’s issue is idiosyncratic versus macro.